Back to search

Article

Metabolic Signatures of Dual mTOR Inhibition in Diffuse Large B-Cell Lymphoma

2026-03-11

Abstract excerpt

<title>Abstract</title> <p> Diffuse large B-cell lymphoma (DLBCL) is an aggressive and heterogeneous malignancy in which many patients relapse or fail to respond to standard therapies. Constitutive activation of the mechanistic target of rapamycin (mTOR) pathway, involving both mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2), promotes tumor growth and metabolic reprogramming. First-generation inhibitors targ...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
c5538f00-37c1-54b9-9d96-5c5a9cd49345
DOI
10.21203/rs.3.rs-8928389/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Metabolic Signatures of Dual mTOR Inhibition in Diffuse Large B-Cell LymphomaDOI 10.21203/rs.3.rs-8928389/v1
Select a neighboring publication to make it the new centre.